March 16, 2022 News by Marisa Wexler, MS Novantrone Lowers Relapses, Eases Disability in Highly Active RRMS Initial treatment with Novantrone (mitoxantrone) can reduce the risk of relapses and worsening disability in people with highly active relapsing-remitting multiple sclerosis (RRMS), according to a 10-year study from France. “Our results support the short-term use of [Novantrone], followed by a maintenance therapy for patients with early highly…
January 23, 2020 Columns by Jennifer (Jenn) Powell The Rise of Superbugs, Antibiotic Resistance, and MS I am living with an unenviable reality. An antibiotic-resistant, hospital-acquired infection that I developed two decades ago has reappeared. Before my multiple sclerosis diagnosis, I had a spinal cord stimulator implanted for pain control. Although the stimulator was removed shortly afterward, the infection remained. This infection presents itself when…
August 9, 2019 News by Jose Marques Lopes, PhD Harnessing T-cell Subtype May Suppress Immune Responses in MS, Study Suggests Though known mainly for killing tumor and virally infected cells, a T-cell subtype may restrain immune responses and be protective in autoimmune diseases such as multiple sclerosis (MS), according to new research. The study, āOpposing T cell responses in experimental autoimmune encephalomyelitis,ā was published recently in…
November 29, 2018 News by Ana Pena PhD Stem Cells With Unusual Metabolism May Be Therapeutic Approach to Fight Inflammatory Diseases Like MS, Study Suggests Human mesenchymal stem cells (hMSCs), the type of stem cells present in many tissues of adults, may be manipulated to fight inflammation and used as a cell therapy to treat inflammatory diseases like multiple sclerosis (MS), a study reports. In the future, researchers plan to use animal models to…
August 17, 2017 News by Patricia Silva, PhD Older Immunosuppressants May Increase MS Patients’ Cancer Risk, Study Reports The risk of people with multiple sclerosis developing cancer is higher if they have used immunosuppressants than if they haven’t, according to a study that followed more than 1,000 patients for a decade. The findingsĀ indicate that the often discussed association between MS and cancer may stem from older types of…
September 15, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Escalation vs. Induction Treatment for Early MS Topic of Debate Two renowned multiple sclerosis (MS) specialistsĀ shared their opposing viewsĀ regarding the use of escalation or induction treatment for newly diagnosed MS patients. The debate was at the Hot Topic 1 Session of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, now taking place in London through…
January 15, 2016 News by Patricia Silva, PhD Potential MS Treatment Targeting CD3 Receptor Moving into Development Tiziana Life Sciences, plc, a biotechnology company specializing inĀ drugs to treat immunological and oncological diseases,Ā recently announced its intentĀ toĀ further develop foralumab, a fully human monoclonal antibody targeting the CD3 receptor. This approach, aimingĀ to modulate the immune T cell response and achieve immunosuppression, is well-validated and has the potential to…